6:31 PM
 | 
Jun 02, 2008
 |  BC Extra  |  Clinical News

ImClone off after Erbitux data

ImClone (NASDAQ:IMCL) fell $2.64 to $40.94 on Monday as investors digested data from multiple presentations on Erbitux cetuximab at the American Society of Clinical Oncology (ASCO) meeting in Chicago. The data included a subgroup analysis of the CRYSTAL trial in 540 evaluable patients with K-Ras (KRAS) wild-type metastatic colorectal cancer (mCRC) and additional data from the FLEX study for advanced non-small cell lung...

Read the full 306 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >